CDM PerpPD+ Analysis (INmune Bio XPro1595)
Alzheimer's Disease (High-Inflammation)
Phase 2Active
Key Facts
Indication
Alzheimer's Disease (High-Inflammation)
Phase
Phase 2
Status
Active
Company
About Oxford Brain Diagnostics
Oxford Brain Diagnostics is a private, commercial-stage diagnostics company leveraging its FDA-cleared and breakthrough-designated MRI biomarker platform to quantify cortical microstructure changes associated with neurodegeneration. Its core technology, CDM®, provides novel endpoints for clinical trials and tools for clinicians, positioning it as a partner for biopharma and a contributor to precision neurology. The company is actively engaged in partnerships and research grants, indicating a transition from technology validation to commercial application in a high-need market.
View full company profile